A FormBlends network publication
The Science

The GIP receptor and why dual agonism is not just more GLP-1

What GIP does on its own, why it looked useless in type 2 diabetes, how tirzepatide engages both receptors unequally, and the unresolved argument over whether turning GIP up or down is the better idea.

By FormBlends editorial teamUpdated September 4, 2026Educational, not medical advice

GIP was the first incretin discovered and the first to be written off. Understanding why it came back explains what a dual agonist actually is.

GIP on its own

GIP is released by K cells in the upper small intestine within minutes of a meal, especially a fatty one. In healthy people it stimulates insulin about as strongly as GLP-1. In 1993 Nauck and colleagues infused each hormone into people with type 2 diabetes and found that GLP-1 kept its insulinotropic effect while GIP had largely lost it (PubMed 8423228). For the next two decades, drug development followed GLP-1 and left GIP alone.

Three things complicated that verdict. GIP's insulin effect in diabetes is partly restored when glucose is brought down, suggesting the loss is a symptom of hyperglycaemia rather than a fixed defect. GIP receptors exist on adipocytes, where GIP promotes lipid uptake and blood flow in fed conditions, which Samms and colleagues argue may improve how fat tissue buffers lipids (PubMed 32396843). And GIP receptors exist in the hypothalamus and brainstem, where GIP signalling reduces food intake in mice (PubMed 33571454).

How tirzepatide engages the GIP and GLP-1 receptors and where each actsTirzepatide at the top splits into two arrows. A thick arrow to the GIP receptor is labelled affinity similar to native GIP. A thinner arrow to the GLP-1 receptor is labelled about five-fold weaker than native GLP-1, biased toward cAMP over beta-arrestin. Below the GIP receptor: beta cell insulin, adipose lipid buffering (proposed), brain intake reduction (mice), and less nausea (animals). Below the GLP-1 receptor: beta cell insulin, alpha cell glucagon down, stomach slowing, brain intake reduction, nausea. A box at the bottom notes that GIP receptor antagonists also reduce weight in animals, so the direction of the GIP effect is debated.Tirzepatide39 amino acids, C20 fatty diacidaffinity close to native GIPabout 5-fold weaker than native GLP-1biased: more cAMP, less beta-arrestinGIP receptorGLP-1 receptorBeta cellinsulin up, returnsas glucose fallshuman, BAdiposelipid buffering,insulin sensitivityproposed, DBrainintake down; less nauseamice and shrews, CIsletsinsulin up,glucagon downhuman, BStomachslower emptying,fades with timehuman, BBrainintake down; nauseahuman intake, BOpen questionGIP receptor antagonists also reduce weight when combined with GLP-1 receptor agonism in mice (Killion 2018).Agonism and antagonism cannot both be the mechanism in the simple sense, so how GIP helps is unresolved.
Figure 3. Two receptors, unequal engagement. Tirzepatide's binding and signalling profile from Willard 2020, downstream targets from Samms 2020 and Hammoud and Drucker 2023. Dashed elements are proposed or debated.

What tirzepatide actually is

Tirzepatide is a 39-amino-acid peptide built on the GIP sequence, with a C20 fatty diacid for albumin binding (PubMed 30473097). Willard and colleagues characterised it as imbalanced and biased: it binds the GIP receptor with affinity close to native GIP but the GLP-1 receptor about five-fold weaker than native GLP-1, and at the GLP-1 receptor it produces cAMP efficiently while recruiting beta-arrestin poorly (PubMed 32730231). Reduced beta-arrestin recruitment slows receptor internalisation, which in cell models sustains signalling. Whether that bias matters clinically is not proven; it is a plausible contributor, not an established mechanism.

The clinical comparison that matters is SURPASS-2. In 1,879 adults with type 2 diabetes on metformin, tirzepatide 15 mg lowered HbA1c by 2.30 percentage points versus 1.86 for semaglutide 1 mg at 40 weeks, and body weight by 11.2 kg versus 5.7 kg (PubMed 34170647). Nausea rates were in the same range for both drugs rather than scaling with the extra weight loss.

The agonist-antagonist paradox

Here is the part most explainers skip. In 2018 Killion and colleagues showed that antibodies blocking the GIP receptor reduced body weight in obese mice and monkeys, and did so additively with a GLP-1 receptor agonist (PubMed 30567927). In 2021 Zhang and colleagues showed the opposite arm: a GIP receptor agonist reduced food intake and weight in mice through receptors in the brain, and the effect disappeared when the central receptor was deleted (PubMed 33571454). Two opposite manipulations, one direction of effect.

Proposed reconciliations include receptor desensitisation (chronic agonism may functionally behave like antagonism), different tissues dominating in different models, and an effect of GIP on the tolerability of GLP-1 receptor activation rather than on weight itself. Borner and colleagues showed GIP receptor agonism reduced GLP-1 receptor agonist-induced emesis in shrews (PubMed 34380697), which would let a dual agonist be pushed to higher effective GLP-1 exposure. Hammoud and Drucker's 2023 review is the fairest summary: the two hormones have contrasting actions in several tissues and the mechanism of the added benefit in humans is not established (PubMed 36509857). This site grades it D, debated, in the mechanism map.

What this means for a reader

Dual agonism is a real pharmacological difference with a proven clinical result and an unproven explanation. Anyone who tells you exactly why tirzepatide out-performs semaglutide is ahead of the evidence. Compounded tirzepatide is not FDA approved, is not the product tested in SURPASS or SURMOUNT, and is not interchangeable with Mounjaro or Zepbound.

Where to go next

Questions people ask

Is tirzepatide just a stronger GLP-1 drug?

No. In receptor assays it favours the GIP receptor and signals through the GLP-1 receptor in a biased way, with more cAMP and less beta-arrestin recruitment than native GLP-1 (PubMed 32730231). Its clinical profile also differs: larger weight loss than semaglutide 1 mg at matched trial conditions, with similar nausea rates rather than proportionally higher ones (PubMed 34170647).

Why did GIP look like a dead end for diabetes?

Because in people with type 2 diabetes, infused GIP had largely lost its ability to stimulate insulin while GLP-1 had not (PubMed 8423228). The later insight was that GIP's value may lie outside the beta cell, in the brain and in adipose tissue, and that its insulin effect returns as glucose comes down.

Sources

  1. Nauck MA, Heimesaat MM, Orskov C, et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993. PubMed 8423228 Accessed September 4, 2026.
  2. Samms RJ, Coghlan MP, Sloop KW. How may GIP enhance the therapeutic efficacy of GLP-1? Trends Endocrinol Metab 2020. PubMed 32396843 Accessed September 4, 2026.
  3. Willard FS, Douros JD, Gabe MB, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight 2020. PubMed 32730231 Accessed September 4, 2026.
  4. Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab 2018. PubMed 30473097 Accessed September 4, 2026.
  5. Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). N Engl J Med 2021. PubMed 34170647 Accessed September 4, 2026.
  6. Killion EA, Wang J, Yie J, et al. Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models. Sci Transl Med 2018. PubMed 30567927 Accessed September 4, 2026.
  7. Zhang Q, Delessa CT, Augustin R, et al. The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling. Cell Metab 2021. PubMed 33571454 Accessed September 4, 2026.
  8. Borner T, Geisler CE, Fortin SM, et al. GIP receptor agonism attenuates GLP-1 receptor agonist-induced nausea and emesis. Diabetes 2021. PubMed 34380697 Accessed September 4, 2026.
  9. Hammoud R, Drucker DJ. Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1. Nat Rev Endocrinol 2023. PubMed 36509857 Accessed September 4, 2026.

Canonical URL: https://formblendsscience.com/mechanisms/gip-receptor-and-dual-agonism. Written by the FormBlends editorial team. This page is educational and is not medical advice; see the medical disclaimer.